Ora

FACT SHEET

Inspiring the Future of Ophthalmic Clinical Development

Preclinical Ophthalmic Research Services

Pairing world class preclinical facilities at the Singapore Eye Research Institute with Ora's 45 years in ophthalmic development, there is no CRO better placed to lend its knowledge and experience to early-stage clients. When conceptualizing and commencing the development pipeline, the ability to think ahead to future stages in the clinical pipeline is vital to ensuring the right activities are done at the preclinical phase and avoid costly rework that can set back timelines. Combined with the Singapore Eye Research Institute's 30 years of preclinical expertise and world class facilities, our experience and expertise when engaging with early-stage clients can truly allow you to begin your program with the end in mind.

About Singapore Eye Research Institute

- **More than 240 Staff Members**
- **60 Principal Investigators**
- **More than 20 Clinician Scientists**
- **750 Ocular Preclinical Studies in the last 5 years**

Renowned for its cutting-edge work in the realms of eye disease and visual science, SERI's research spans basic, clinical, and translational efforts involving experts in ophthalmology, molecular biology, genetics, bioengineering, AI, epidemiology, and population health.

SERI has grown from a founding team of five in 1997 to an integrated organization of more than 240 staff, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in the Asia Pacific region, publishing an impressive array of more than 5,000 scientific papers.

SERI undertakes vision research in collaboration with local clinical ophthalmic centers and biomedical research institutions, as well as major eye centers and research institutes throughout the world. One of the key strengths of SERI is its multidisciplinary, collaborative approach to research that has led to breakthroughs in understanding and treating eye diseases, resulting in innovative diagnostic and therapeutic approaches.

Robust Animal Models

- Full range of animal models including, Non-human Primate facility for non-GLP pre-clinical research
- Both experimentally induced and transgenic/gene knock out animal models

Multi-Disclipinary Team

- Fully trained/skilled in ophthalmic imaging for small & large animals
- A team of scientists, clinician scientists, clinicians, veterinarians, and technical staff

State of the Art Facility

- Full ophthalmic imaging set up for small & large animals
- AAALAC accredited animal facility
- NACLAR, NC3R Guidelines
- ABSL1; ABSL2; ABSL3
- Full ophthalmic surgical capabilities for both small and large animals
- Breeding for small and large animals-transgenic mice

Full Surgical and Imaging Capabilities

- In-vivo Confocal Microscopy System
- Femto-second laser
- Technolas Excimer Laser
- Focal Domain OCT
- SD OCT
- IOL Master
- Micron IV
- UBM
- Pneumotonometer
- AS OCT
- Auto-refractometer
- Retinoscope
- A Scan
- Tonovet
- Tonopen
- Ocumetrics Fluortron Master
- Slit lamp bio-microscopy
- Full suite of surgical capabilities for small and large animals

Full Scope of Ocular Animal Efficacy Models

		Chick	Mouse	Rat	Guinea Pig	Rabbit	Pig	NHP
Anterior Segment	Corneal Fibrosis					●		
	Allergic Conjunctivitis		●					
	Keratoplasty Model			●				
	Epithelial / Stromal Corneal Wound		●	●		●		
	Refractive Models		●	●		●		
	Phacoemulsification for Cataract					●		
	Dry Eye		●	●		●		
	Uveitis			●		●	●	
Posterior Segment	Myopia	●	●		●			●
	Glaucoma		●	●				
	Proliferative Vitreoretinopathy					●	●	
	CNV for Wet AMD		●	●		●		●
	Retinal Fibrosis		●	●				
	PRNV					●		
	Dry AMD		●					●
	Retinitis Pigmentosa		●			●		
	Retinal Degeneration		●			●		
	Inherited Retinal Degeneration		●	●		●		●
	Stargardt's Disease		●					
	Retinal Atrophy		●	●				●
	PDR / DR / OIR / DME		●					

Beginning with the end in mind

The first steps in any journey are crucial. Ora's decades of experience in ophthalmic development can ensure that you begin your program with the end in mind.

Ora's experts, combined with world class full turnkey preclinical facilities at SERI can help you de-risk your entire clinical program by considering your regulatory, clinical, and investment strategies when designing your preclinical phase.

The Ora Early-Stage Collaborative Approach

Regulatory
From designing your preclinical programming to interpreting data and presenting to regulatory agencies.

Investment
Finding the right data points to de-risk your investment strategy.

Clinical
Liaising with Ora's Therapeutic Area Experts to enable a seamless transition into the clinic.

Leading the charge for this collaboration is Buffie Kerstetter, Director of Preclinical Partnerships, a tenured preclinical business development advocate for Ora's valued sponsors in preclinical development. Prior to working at Ora Buffie has spent her entire 30-year career working with animals in research as a certified lab animal technologist and providing oversight of animal programs and staff at several large institutions.

Reach out to bkerstetter@oraclinical.com for more information.

Buffie Kerstetter
Director of Preclinical Partnerships

Ora is a global full-service ophthalmic drug and device development firm with vast capabilities through all steps of clinical research, including preclinical, clinical, CMC & regulatory, and patient and site evaluations. Through Ora's 40+ years of experience, the company has assisted in bringing more than 80 products to market. Ora's team of experts utilizes global regulatory strategies, integrated research operations, and extensive site and patient engagement to accelerate product development in anterior and posterior segment, as well as ophthalmic devices.